IPP Bureau

Roche BTK drug emerges as potential breakthrough in primary progressive MS
Roche BTK drug emerges as potential breakthrough in primary progressive MS

By IPP Bureau - February 10, 2026

Antara Senior Care launches second Chennai care home amid growing senior population
Antara Senior Care launches second Chennai care home amid growing senior population

By IPP Bureau - February 10, 2026

The new OMR facility, located in Chennai’s medical hub, is close to leading hospitals and offers excellent road and air connectivity

Ajooni Biotech bags record Rs. 47.52 crore order
Ajooni Biotech bags record Rs. 47.52 crore order

By IPP Bureau - February 10, 2026

The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production

Entero Healthcare expands MedTech footprint with acquisition of Anand Chemiceutics
Entero Healthcare expands MedTech footprint with acquisition of Anand Chemiceutics

By IPP Bureau - February 10, 2026

Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions

Zydus Lifesciences reports strong Q3 & 9M FY26 growth
Zydus Lifesciences reports strong Q3 & 9M FY26 growth

By IPP Bureau - February 10, 2026

Revenue from operations surged 30% year-on-year to Rs. 68,645 million

GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth
GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth

By IPP Bureau - February 10, 2026

Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum

Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26
Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26

By IPP Bureau - February 10, 2026

The revenues this quarter are in line with the outlook we envisaged for the year

Time Medical India unveils next-generation MRI platforms at IRIA 2026
Time Medical India unveils next-generation MRI platforms at IRIA 2026

By IPP Bureau - February 10, 2026

The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology

SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track
SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track

By IPP Bureau - February 10, 2026

The company’s EBITDA margin remained resilient above 20%

Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive
Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive

By IPP Bureau - February 09, 2026

The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses

HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology
HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology

By IPP Bureau - February 09, 2026

HCG clinicians contributing to one of the largest bodies of oncology research from India

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles

By IPP Bureau - February 09, 2026

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26

DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies
DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies

By IPP Bureau - February 09, 2026

Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments

Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder
Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder

By IPP Bureau - February 09, 2026

LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution

Biomica seals exclusive global license for groundbreaking microbiome cancer therapy
Biomica seals exclusive global license for groundbreaking microbiome cancer therapy

By IPP Bureau - February 09, 2026

The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer

Latest Stories

Interviews

Packaging